Hospital
Siloam Springs Arkansas Hospital Company LLC
Siloam Springs Arkansas Hospital Company LLC was paid $4.99M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoSILOAM SPRINGS ARKANSAS HOSPITAL COMPANY LLC
SILOAM SPRINGS, AR 72761
SILOAM SPRINGS, AR 72761
33aNPI1902051816assigned 11/19/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.99M
24GClaims228,566
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#16 of 49
Median peer was paid$2.62M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,783 | $579K | |
| 2019 | 22,366 | $629K | |
| 2020 | 19,557 | $429K | |
| 2021 | 32,338 | $691K | |
| 2022 | 44,685 | $1.03M | |
| 2023 | 50,467 | $1.01M | |
| 2024incomplete | 38,370 | $627K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 10,742 | 9,707 | $1.26M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 5,532 | 4,751 | $643K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.1% | 2,729 | 2,237 | $352K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 6.1% | 9,524 | 8,421 | $304K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.9% | 2,700 | 2,248 | $244K |
| 80053 | Comprehensive metabolic panel | 4.6% | 15,218 | 12,291 | $228K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.2% | 9,820 | 8,577 | $211K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 17,253 | 13,296 | $118K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 6,489 | 5,005 | $81K |
| 87430 | 1.6% | 6,400 | 5,817 | $80K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 2,397 | 1,863 | $72K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 7,020 | 5,100 | $69K |
121 more codes
| 59025 | Fetal non-stress test | 1.4% | 482 | $68K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 2,308 | $64K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 977 | $63K |
| 80306 | 1.2% | 3,975 | $59K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 891 | $53K |
| 81001 | <1% | 14,957 | $50K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,316 | $48K |
| 83880 | <1% | 1,360 | $46K | |
| 81025 | <1% | 5,947 | $44K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 384 | $43K |
| 84484 | <1% | 5,590 | $43K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,993 | $37K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 543 | $36K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,980 | $34K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 495 | $32K |
| 83690 | <1% | 5,047 | $32K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,592 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,951 | $30K |
| 99285 | Emergency room visit (most serious) | <1% | 1,189 | $28K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,148 | $26K |
| 85027 | <1% | 5,236 | $25K | |
| 87081 | <1% | 2,657 | $24K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 473 | $24K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,089 | $22K |
| 82077 | <1% | 1,371 | $20K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,455 | $20K |
| 87807 | <1% | 1,562 | $18K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,885 | $17K |
| 73630 | <1% | 729 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,910 | $15K |
| 82962 | <1% | 3,246 | $15K | |
| 86901 | <1% | 984 | $14K | |
| 87040 | <1% | 1,691 | $14K | |
| 73610 | <1% | 780 | $14K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 914 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,674 | $12K |
| 73130 | <1% | 452 | $10K | |
| 83605 | <1% | 1,185 | $10K | |
| 80061 | Lipid panel | <1% | 1,664 | $10K |
| 80143 | <1% | 527 | $9K | |
| 80179 | <1% | 540 | $8K | |
| 73562 | <1% | 289 | $8K | |
| 73110 | <1% | 371 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,542 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 341 | $7K |
| 83735 | <1% | 1,533 | $7K | |
| 93970 | <1% | 328 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 168 | $7K |
| 73030 | <1% | 349 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 169 | $6K |
| 86850 | <1% | 645 | $6K | |
| 85610 | <1% | 2,311 | $5K | |
| 87088 | <1% | 645 | $5K | |
| 90715 | <1% | 404 | $5K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $3K |
| 87077 | <1% | 371 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 490 | $3K |
| 85730 | <1% | 736 | $3K | |
| 71020 | <1% | 191 | $3K | |
| 97161 | <1% | 105 | $3K | |
| 96376 | <1% | 81 | $2K | |
| 43235 | <1% | 21 | $2K | |
| 74018 | <1% | 111 | $2K | |
| 86900 | <1% | 813 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 580 | $2K |
| 71010 | <1% | 297 | $2K | |
| 87186 | <1% | 272 | $1K | |
| 86140 | <1% | 230 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,458 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,775 | $1K |
| 85379 | <1% | 125 | $1K | |
| 84702 | <1% | 138 | $984.37 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,920 | $977.70 |
| 73502 | <1% | 62 | $876.77 | |
| 97162 | <1% | 17 | $741.60 | |
| 82150 | <1% | 102 | $725.21 | |
| 80076 | <1% | 50 | $690.06 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,047 | $666.35 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 20 | $542.43 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,384 | $519.87 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 934 | $453.76 |
| 73140 | <1% | 12 | $386.51 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 81 | $366.02 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 245 | $352.07 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,103 | $319.22 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 34 | $284.39 |
| 73090 | <1% | 14 | $282.39 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 330 | $247.85 |
| 74000 | <1% | 15 | $240.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,102 | $229.36 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 129 | $192.26 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 206 | $190.20 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 253 | $172.67 |
| 73560 | <1% | 17 | $166.27 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 17 | $141.28 |
| 82803 | <1% | 16 | $110.52 | |
| 87070 | <1% | 14 | $104.21 | |
| 94760 | <1% | 21 | $56.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 14 | $54.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 119 | $43.51 |
| 84439 | <1% | 12 | $38.64 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 83 | $30.41 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 87 | $27.85 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 899 | $26.77 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 33 | $20.76 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 36 | $15.66 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 42 | $12.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 50 | $4.50 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 64 | $1.86 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 445 | $0.00 |
| 97116 | 0% | 26 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 66 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 21 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 129 | $0.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 39 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 229 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 71 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 34 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 14 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.